Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings
Article first published online: 25 DEC 2001
© 2000 Blackwell Science Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Volume 15, Issue 3, pages 227–229, March 2000
How to Cite
Freiman, J. S. and M, G. W. (2000), Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings. Journal of Gastroenterology and Hepatology, 15: 227–229. doi: 10.1046/j.1440-1746.2000.02129.x
- Issue published online: 25 DEC 2001
- Article first published online: 25 DEC 2001
- 1The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hepatitis Reviews 1996; 2: 1 35.&
- 10A pre-transplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti hepatitis B virus surface antigen immunoprophylaxis. Hepatology 1997; 26: 478 84., , et al.
- 15Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant associated infection. High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transplant Surg. 1999; 5: 512 19., , et al.
- 16Prophylactic lamivudine and very low dose HBIG prevent HBV recurrence post liver transplant whilst rescue therapy with lamivudine is associated with significant resistance and graft loss. Hepatology 1998; 28: 263A., , et al.
- 21Three year lamivudine therapy in chronic HBV. J Hepatol. 1999; 30 (Suppl.): 59 (Abstract)., , et al.